Calendario›OPK›MOD-6031

MOD-6031

A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects

Ensayo de OPKO HEALTH, INC. en Obesidad.

Más ensayos de: Obesidad.

Fase

Fase 1

Estado

Completado

Participantes

32

previstos

Centros

1

Fin del objetivo primario

dic 2016

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, simple ciego. Comenzó en feb 2016.

Qué mide

Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), laboratory results, vital signs and injection site reactions (del registro, en inglés) (30 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroMOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM and is an agonist for both glucagon-like peptide-1 (GLP1) and glucagon (GCG) receptors. The peptide is a natural appetite suppressant, secreted by L-cells in the digestive system following food intake leading to a decrease in gastric emptying, satiety after crossing the blood-brain barrier, and regulation of insulin and glucose levels. Thus, MOD-6031 is being developed as a treatment for high risk subjects (obese) to increase weight loss, reduce food intake and increase glycemic control.

Más ensayos de OPK

Todos los de OPK, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02692781), actualizada en sep 2019.